4-Dimethylamino-3-(4-methoxyphenyl)-3-buten-2-one | 306739-55-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Dimethylamino-3-(4-methoxyphenyl)-3-buten-2-one
• 英文别名: (E)-4-dimethylamino-3-(4-methoxyphenyl)-3-butene-2-one；4-dimethyl-amino-3-(4-methoxyphenyl)-3-buten-2-one；(E)-4-(dimethylamino)-3-(4-methoxyphenyl)but-3-en-2-one
• CAS: 306739-55-9
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: KEGMAEFVJNPESF-LCYFTJDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Dimethylamino-3-(4-methoxyphenyl)-3-buten-2-one 在 盐酸 、 potassium tert-butylate 、 氨 、 对甲基苯磺酰异氰酸酯 作用下， 以 乙醚 、 水 、 异丙醇 、 甲苯 为溶剂， 反应 108.0h， 生成 4-amino-5-(4-methoxyphenyl)-2-(trifluoromethyl)pyridine
  参考文献：
  名称：

  通过4-氨基-5-芳基-2-（三氟甲基）吡啶由4个H-吡喃-4-酮取代合成3-（三氟甲基）苯并[ c ] [1,6]萘啶

  摘要：

  在P 2 O 5 / POCl 3的作用下，酰化的4-氨基-5-芳基-2-（三氟甲基）吡啶的环化反应平稳地提供了3-（三氟甲基）苯并[ c ] [1,6]萘啶。由相应的4 H-吡喃-4-酮按两步顺序合成中间体氨基吡啶，它们是通过2-乙酰基-2-芳基环氧乙烷与4-二甲基氨基-3-（4-甲氧基苯基）-3-的反应制备的在碱性条件下将丁烯-2-酮与三氟乙酸乙酯混合。

  DOI：

  10.1016/s0040-4020(00)00637-2
• 作为产物：
  描述：

  对甲氧基苯基丙酮 、 N,N-二甲基甲酰胺二乙基缩醛 生成 4-Dimethylamino-3-(4-methoxyphenyl)-3-buten-2-one
  参考文献：
  名称：

  5-Substituted pyranone compounds and their use as pharmaceuticals to

  摘要：

  化合物的分子式为##STR1##其中R.sup.1是COOR.sup.5，CONHR.sup.5，氰基，5-四唑基或5-四唑基氨基甲酰，其中R.sup.5是氢或C.sub.1-6烷基；R.sup.2是氢或C.sub.1-6烷基；R.sup.3是R.sup.6--(Z).sub.m--的基团，其中m为O或1，Z为O，S，SO，SO.sub.2或CO，R.sup.6是苯基，可以选择地取代一个或多个来自卤素，C.sub.1-4烷基，C.sub.3-6环烷基，C.sub.1-4烷氧基，苄氧基，羟基，硝基，C.sub.1-4烷基硫基，C.sub.1-4烷基亚硫酰基，C.sub.1-4烷基磺酰基，氨基和NHR.sup.7的基团，其中R.sup.7是C.sub.2-6酰基；R.sup.4是氢，C.sub.1-6烷基或卤素；及其盐。这些化合物具有药用特性，特别是在治疗哮喘等即时过敏症状方面有用。

  公开号：

  US04364956A1

文献信息

• [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY<br/>[FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004033444A1

  公开（公告）日：2004-04-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones,
  申请人：Sterling Drug Inc.

  公开号：US04465686A1

  公开（公告）日：1984-08-14

  Disclosed and claimed is the cardiotonic use of 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (II), where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R" are each hydrogen, amino or hydroxy, at least one of R' or R" being other than hydrogen, or where R' is nitro when R" is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R" is amino. Also disclosed and claimed are 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (I), where R.sub.1, R' and R" are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R" is amino. Also shown and claimed is the process which comprises reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-(3-R'-4-R"-phenyl)-6-R-nicotinonitrile, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R" is hydroxy, methoxy or hydrogen, preferably at least one of R' and R" being methoxy, or where R' is nitro and R" is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinone.

  揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮（II）的强心作用，其中R.sub.1为氢、低烷基或低羟基烷基，R为低烷基或氢，R'和R"分别为氢、氨基或羟基，其中至少有一个R'或R"不是氢，或者当R"为羟基时，R'为硝基，或其药学上可接受的酸加合物盐，其中至少一个R'和R"为氨基。还揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮（I），其中R.sub.1、R'和R"的定义如上所述，R为低烷基，以及其药学上可接受的酸加合物盐，其中至少一个R'和R"为氨基。还显示和声明了一种过程，包括将1-R.sub.1 -1,2-二氢-2-氧代-5-(3-R'-4-R"-苯基)-6-R-烟酸腈与85%磷酸反应，其中R.sub.1和R的定义如上所述用于II，R'为氢、羟基、甲氧基或氨基，R"为羟基、甲氧基或氢，最好是R'和R"中至少一个为甲氧基，或者当R'为硝基且R"为氢或甲氧基时，最好为甲氧基，以产生1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮。
• 3-Amino-5-(hydroxy- and/or
  申请人：Sterling Drug Inc.

  公开号：US04515797A1

  公开（公告）日：1985-05-07

  1-R.sub.1 -3-amino-5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones or salts thereof, which are useful as cardiotonics, where R.sub.1 is hydrogen, lower-alkyl, or lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and, R' and R" are each hydrogen, hydroxy or amino at least one of R' or R" being other than hydrogen, are prepared by reacting the corresponding 3-carbamyl compound with a reagent capable of converting carbamyl to amino or by first reacting the corresponding 3-carbamyl compound where R' and R" are each hydrogen, nitro or lower-alkoxy at least one of R' and R" being other than hydrogen with a reagent capable of converting carbamyl to amino and then reacting the resulting 3-amino compound where R' and/or R" are/is lower-alkoxy and/or nitro with a reagent capable of converting lower-alkoxy to hydroxy and/or with a reagent capable of converting nitro to amino. Preparation of the corresponding 3-carbamyl and 3-cyano compounds is shown, the latter including cardiotonically active novel 1-R.sub.1 -1,2-dihydro-5-(3-R.sub.2 -4-R.sub.3 -phenyl)-6-R-nicotinonitriles where R.sub.1 and R are defined as above, and R.sub.2 and R.sub.3 have the above given definitions for R' and R" or where R.sub.2 is nitro and R.sub.3 is hydroxy. Also shown are cardiotonic compositions and cardiotonic method of use of above-said compounds.

  1-R.sub.1 -3-氨基-5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮或其盐，可用作心脏强心剂，其中R.sub.1是氢、低烷基或低羟基烷基，R是氢或低烷基，R'和R"分别是氢、羟基或氨基，其中R'或R"至少有一个不是氢，通过将相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应制备，或者首先将R'和R"分别是氢、硝基或低烷氧基，其中R'和R"中至少有一个不是氢的相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应，然后将所得的3-氨基化合物与能够将低烷氧基转化为羟基和/或能够将硝基转化为氨基的试剂反应，其中R'和/或R"是低烷氧基和/或硝基。显示了相应的3-氨基甲酰和3-氰基化合物的制备，后者包括具有心脏强心活性的新颖的1-R.sub.1 -1,2-二氢-5-(3-R.sub.2 -4-R.sub.3 -苯基)-6-R-烟酰腈，其中R.sub.1和R如上所定义，R.sub.2和R.sub.3具有上述给定的R'和R"的定义，或者其中R.sub.2是硝基，R.sub.3是羟基。还显示了心脏强心剂组合物和上述化合物的心脏强心方法的用途。
• Substituted phenyl-2-(1H)-pyrimidinones useful for treating cardiac
  申请人：Beiersdorf Aktiengesellschaft

  公开号：US04582834A1

  公开（公告）日：1986-04-15

  New substituted phenyl-2-(1H)-pyrimidinones of the general formula I ##STR1## in which R.sup.1 denotes an alkyl group having 1 to 4 carbon atoms, and R.sup.2 and R.sup.3, which can be identical or different, each denote hydrogen, halogen, cyano, a trifluoromethyl group, a hydroxyl group or an alkoxy group having 1 to 4 carbon atoms, it being possible for each alkyl moiety to be straight-chain or branched, and their tautomeric forms and their acid addition salts and N-oxides have a positive inotropic effect and can thus be used as medicaments for the treatment of cardiac insufficiency.

  通式I为新的取代苯基-2-(1H)-嘧啶酮，其中R1表示1至4个碳原子的烷基，R2和R3可以相同也可以不同，分别表示氢、卤素、氰基、三氟甲基、羟基或1至4个碳原子的烷氧基，每个烷基可以是直链或支链，它们的互变异构体、酸加成盐和N-氧化物具有正性肌力作用，因此可用作治疗心力衰竭的药物。
• Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
  申请人：ARTESIAN THERAPEUTICS, INC.

  公开号：US20040242648A1

  公开（公告）日：2004-12-02

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对PDE-3和L型钙通道的抑制活性的化合物。本发明还提供了包含这种化合物的药物组合物和使用这种化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。